Member Sign In

You are being directed to ZacksTrade, a division of Zacks & Company and licensed broker-dealer. ZacksTrade and Zacks.com are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

Glaxo Seeks Albiglutide Approval

You have chosen to follow this author. You will receive an email notification when this author publishes a new article. Click submit to continue.

You are alredy following the Author

The Author could not be added at this time, please try again later. If problem persists, please contact Zacks Customer support.

Please Login

GlaxoSmithKline (GSK - Analyst Report) recently announced the submission of a marketing application to the US Food and Drug Administration (FDA) for its diabetes candidate albiglutide. The companies are looking to get the candidate approved for treating adults suffering from type II diabetes (once weekly).

The company is planning to submit a regulatory application to the European Medicines Agency (EMA) in early 2013.

The marketing application includes data from a phase III study (Harmony 8). We note that in Jul 2012, Glaxo reported encouraging results from the Harmony 8 study, which evaluated albiglutide versus Merck’s (MRK - Analyst Report) Januvia (sitagliptin). Approximately 507 type II diabetes patients with renal impairment were enrolled in the study. The drugs were compared on the basis of reduction in HbA1c, an indicator of glucose level in the blood. Albiglutide showed a statistically significant reduction in HbA1c from the baseline. Results showed that the reduction in HbA1c for albiglutide and Januvia arm were 8.08% and 8.22%, respectively. Additionally, the rate of weight loss was higher in the albiglutide arm.

A few weeks ago, Glaxo and its partner Theravance, Inc. (THRX - Analyst Report) announced the submission of a marketing application to the EMA for their pipeline candidate UMEC/VI (proposed trade name: Anoro). The companies are looking to get the candidate approved in the EU as a maintenance bronchodilator therapy (once daily) to relieve symptoms in adults suffering from chronic obstructive pulmonary disease (COPD).

Glaxo/Theravance are also seeking US approval of the candidate for the COPD indication. Last month, the companies announced the submission of a marketing application with the FDA seeking approval of UMEC/VI for the COPD indication.

We are positive on advancement of Glaxo’s pipeline programs. We believe the candidates hold immense commercial potential.

Top Zacks Features

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

Zacks Research is Reported On:

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.

Visit performance for information about the performance numbers displayed above.